Reprogrammed Interchange LLC sold 73,676 Vor Biopharma shares

Rhea-AI Filing Summary

Vor Biopharma (VOR): Form 4 insider sales reported. A reporting group including Reprogrammed Interchange LLC sold a total of 73,676 shares of Vor Biopharma common stock on 10/15/2025 and 10/16/2025. The transactions were executed at weighted average prices of $31.0496, $32.0459, $32.7733, and $30.4548.

Following these sales, 1,204,442 shares were beneficially owned as reported after the final transaction. The securities are held by Reprogrammed Interchange LLC; per the disclosure, Reid Hoffman may be deemed a beneficial owner through shared control and indirect pecuniary interest, and he disclaims beneficial ownership except to the extent of his pecuniary interest. Each sale was executed in multiple trades within disclosed price ranges.

Insider Trade Summary

Net Seller: 73,676 shares ($2,348,744)

Net Sell 4 txns

Insider Reprogrammed Interchange LLC, Hoffman Reid

Role 10% Owner | 10% Owner

Sold 73,676 shs ($2.35M)

Type	Security	Shares	Price	Value
Sale	Common Stock	2,021	$30.4548	$62K
Sale	Common Stock	14,851	$31.0496	$461K
Sale	Common Stock	48,910	$32.0459	$1.57M
Sale	Common Stock	7,894	$32.7733	$259K

Holdings After Transaction: Common Stock — 1,204,442 shares (Direct)

Footnotes (1)

1. This transaction was executed in multiple trades at prices ranging from $30.505 to $31.50. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. The securities are held by Reprogrammed Interchange LLC ("Reprogrammed"). Reid Hoffman may be deemed a beneficial owner of securities held by Reprogrammed by virtue of his shared control over and indirect pecuniary interest in Reprogrammed. Mr. Hoffman disclaims beneficial ownership of the securities held by Reprogrammed, except to the extent of his pecuniary interest therein. This transaction was executed in multiple trades at prices ranging from $31.51 to $32.505. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. This transaction was executed in multiple trades at prices ranging from $32.51 to $33.01. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. This transaction was executed in multiple trades at prices ranging from $30.05 to $30.50. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Reprogrammed Interchange LLC

(Last) (First) (Middle)

101 MISSION STREET, SUITE 1000

(Street)

SAN FRANCISCO CA 94105

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Vor Biopharma Inc. [ VOR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
10/15/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/15/2025		S		14,851	D	$31.0496(1)	1,263,267(2)	D
Common Stock	10/15/2025		S		48,910	D	$32.0459(3)	1,214,357(2)	D
Common Stock	10/15/2025		S		7,894	D	$32.7733(4)	1,206,463(2)	D
Common Stock	10/16/2025		S		2,021	D	$30.4548(5)	1,204,442(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

1. Name and Address of Reporting Person^*

Reprogrammed Interchange LLC

(Last) (First) (Middle)

101 MISSION STREET, SUITE 1000

(Street)

SAN FRANCISCO CA 94105

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

Hoffman Reid

(Last) (First) (Middle)

101 MISSION STREET, SUITE 1000

(Street)

SAN FRANCISCO CA 94105

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

Explanation of Responses:

1. This transaction was executed in multiple trades at prices ranging from $30.505 to $31.50. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

2. The securities are held by Reprogrammed Interchange LLC ("Reprogrammed"). Reid Hoffman may be deemed a beneficial owner of securities held by Reprogrammed by virtue of his shared control over and indirect pecuniary interest in Reprogrammed. Mr. Hoffman disclaims beneficial ownership of the securities held by Reprogrammed, except to the extent of his pecuniary interest therein.

3. This transaction was executed in multiple trades at prices ranging from $31.51 to $32.505. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

4. This transaction was executed in multiple trades at prices ranging from $32.51 to $33.01. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

5. This transaction was executed in multiple trades at prices ranging from $30.05 to $30.50. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

	/s/ Reid Hoffman	10/17/2025
	/s/ Frank Huang, Manager of Reprogrammed Interchange LLC	10/17/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Vor Biopharma (VOR) insiders report on Form 4?

A reporting group that includes Reprogrammed Interchange LLC disclosed open-market sales totaling 73,676 shares of Vor Biopharma common stock.

On what dates were the VOR shares sold?

Sales occurred on 10/15/2025 and 10/16/2025.

At what prices were the VOR shares sold?

Weighted average sale prices were $31.0496, $32.0459, $32.7733, and $30.4548. Each sale comprised multiple trades within disclosed ranges.

How many VOR shares were beneficially owned after the transactions?

Following the final sale, reported beneficial ownership was 1,204,442 shares.

Who held the sold securities and what is the relationship to Reid Hoffman?

The securities are held by Reprogrammed Interchange LLC. The filing states Reid Hoffman may be deemed a beneficial owner via shared control and indirect pecuniary interest and disclaims beneficial ownership except to that extent.

Were the VOR sales executed as multiple trades?

Yes. The filing notes multiple trades for each transaction with price ranges disclosed for each date.